MAPT and Alzheimer disease: In the general population and outside of DS, OSA, and sleep disruptions are associated with an increased risk of Alzheimer’s disease (AD), through oxidative stress, metabolic and vascular deregulation, increased inflammation, and by altering amyloid-beta (Aβ) and tau production, phosphorylation, and clearance [11, 14, 15].